{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:08:44Z","timestamp":1783645724820,"version":"3.55.0"},"reference-count":15,"publisher":"Informa Healthcare","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1517\/14712598.2013.837881","type":"journal-article","created":{"date-parts":[[2013,9,20]],"date-time":"2013-09-20T04:40:37Z","timestamp":1379652037000},"page":"1489-1493","source":"Crossref","is-referenced-by-count":2,"title":["Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different"],"prefix":"10.1517","volume":"13","author":[{"given":"Muhammad Wasif","family":"Saif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3197","published-online":{"date-parts":[[2013,9,19]]},"reference":[{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2011.05.005"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-013-0281-x"},{"key":"CIT0004","unstructured":"Zaltrap [prescribing information]. Regeneron Pharmaceuticals, Inc.\/sanofi-aventis U.S. LLC; Bridgewater, NJ: 2012"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.8201"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70477-1"},{"key":"CIT0009","doi-asserted-by":"crossref","first-page":"abstract 3505","DOI":"10.1200\/jco.2012.30.4_suppl.561","volume":"30","author":"Allegra CJ","year":"2012","journal-title":"J Clin Oncol"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1517\/14712590802666397"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1126\/science.1104819"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2276"},{"key":"CIT0013","first-page":"239","volume":"6","author":"Escudero-Esparza A","year":"2009","journal-title":"Cancer Genomics Proteomics"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.8252"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-011-9249-6"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2011.04.014"},{"key":"CIT0017","volume-title":"Summary of product characteristics","author":"Zaltrap","year":"2013"},{"key":"CIT0018","unstructured":"Avastin [prescribing information]. Genentech, Inc; South San Francisco, CA: 2013"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14712598.2013.837881","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T04:24:47Z","timestamp":1563942287000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14712598.2013.837881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,19]]},"references-count":15,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2013,8,6]]},"published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1517\/14712598.2013.837881"],"URL":"https:\/\/doi.org\/10.1517\/14712598.2013.837881","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,19]]}}}